Actinium Pharmaceuticals raises $5.1M for drug development

12/27/2012 | PharmaLive.com

Actinium Pharmaceuticals, which specializes in alpha radioimmunotherapies for advanced cancers, has raised $5.1 million in a funding round. The company said it will use the money to advance its lead drug candidate for acute myeloid leukemia, Actimab-A, and its bone marrow conditioning agent Iomab-B, used in preparing patients for hematopoietic stem cell transplants.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI